September 24, 2020


Vifor Pharma announces outcome of AFFIRM-AHF topline data

  • The study narrowly missed statistical significance on the primary endpoint
  • Pre-specified adjustment of COVID-19 impact, the study showed a statistically significant advantage
  • The totality of evidence suggests that Ferinject® is clinically beneficial in high risk heart failure patients

Regulatory News:

Vifor Pharma today announced topline data from its AFFIRM-AHF study evaluating the effect of Ferinject®"...

Continue Reading >

September 20, 2020


The Epidemiological Situation In Europe Will Delay The Opening Of Algeria’s Borders

The Algerian authorities are moving to postpone the opening of the land and air borders, especially with the countries of the northern bank of the Mediterranean, the first destination for Algerians, and this is due to the infection curve that has reached frightening levels in these countries, and the fear of opening an infection front that has uncalculated consequences for the country in light of a continuous decrease in the pandemic for weeks in Algeria which the authorities consider “an asset that must be preserved”.


Continue Reading >

September 20, 2020


Takeda Presents New Data Highlighting Scientific Advancements in Lung Cancer at ESMO Virtual Congress

Takeda Pharmaceutical Company Limited (TSE:4502/NYSE:TAK) (“Takeda”) today announced that the company is presenting data from its lung cancer portfolio at the virtual European Society for Medical Oncology (ESMO) conference. Notably, insights from sub-analyses of the Phase 3 ALTA 1L study reinforce both the compelling evidence of intracranial efficacy with ALUNBRIG® (brigatinib) as a first-line treatment for patients with anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) as well as associated quality of life (QoL) data. Takeda is also featuring updated 10-month follow-up results from the Phase 1/2 trial of mobocertinib (TAK-788), demonstrating mobocertinib achieved a duration of response (DoR) of more than one year in the trial’s study population of patients with epidermal growth factor receptor (EGFR) Exon20 insertion+ metastatic NSCLC (mNSCLC). “We’re pleased to present our ongoing research in lung cancer at this year’s virtual ESMO congress, including new results from our ongoing Phase 3 ALTA 1L......

Continue Reading >

September 18, 2020


Patient recruitment starts for the international PRO-SID study evaluating Panzyga® for primary prophylaxis in patients with chronic lymphocytic leukaemia and secondary immunodeficiency

Octapharma is pleased to announce that the first site for the international PRO-SID (Primary Infection Prophylaxis with Panzyga® in Secondary Immunodeficiency in Chronic Lymphocytic Leukaemia) study was initiated in Milan, Italy, and patient recruitment is underway. Additional sites across Europe (Italy, Poland, Denmark, Hungary, Germany and Russia) and the USA are expected to begin recruitment soon. PRO-SID is the first randomised, placebo-controlled study to systematically evaluate the efficacy and safety of IVIG for"...

Continue Reading >

September 18, 2020


Vifor Pharma Group Announces Successful Sale of OM Pharma

  • Vifor Pharma to sell 100% of OM Pharma to Optimus Holding Ltd. for a consideration of MCHF 435
  • In addition Vifor Pharma obtains an earn out related to potential future value gains on 20% of Optimus Holding Ltd. equity which could increase the total transaction value in excess of MCHF 500
  • Closure of the transaction is expected within 30 days
  • Divestment strengthens Vifor Pharma’s focus on becoming the global leader in iron deficiency, nephrology and cardio-renal therapies


Continue Reading >

September 17, 2020



  • First clinical study to evaluate novel combination blocking KRAS G12C and its activator SOS1 to potentially increase the therapeutic benefit for lung and colorectal cancer patients
  • Study is based on preclinical evidence suggesting synergistic effect of KRAS G12C and SOS1 inhibition

Boehringer Ingelheim and Mirati Therapeutics, Inc. (NASDAQ: MRTX) today announced a clinical collaboration to evaluate the combination of BI 1701963, a SOS1::pan-KRAS inhibitor blocking KRAS independent of mutation"...

Continue Reading >

September 16, 2020


Sir Richard Branson Joins Dr. Anthony Fauci and Dr. Sanjay Gupta as Keynote Speakers for Everbridge’s Virtual Symposium, COVID-19: Road to Recovery (R2R), October 14-15, 2020

Everbridge, Inc. (NASDAQ: EVBG), the global leader in critical event management (CEM), today announced the addition of premier keynotes and other business, healthcare and government executive speakers for its Autumn 2020 “COVID-19 R2R: The Road to Recovery” virtual leadership summit to be held October 14-15, 2020, covering the path forward amid the COVID-19 pandemic. Virgin Group Founder Sir Richard Branson joins presidential advisor and Director of the National Institute of Allergy and Infectious Diseases (NIAID) at the U.S. National Institutes of Health (NIH) Dr. Anthony Fauci and renowned neurosurgeon and CNN Chief Medical Correspondent Dr. Sanjay Gupta as keynote speakers. Additional speakers, including a world leader, will be announced at a later date. To register for this leadership event, please visit Everbridge’s event registration page. Everbridge’s two-day event will feature C-level speakers from many of the world’s leading organizations including Accenture, Aviva, Capital One, the CDC Foundation, Fortinet, Houston Methodist......

Continue Reading >

September 16, 2020


Sharjah Ladies Club Promotes Healthy Living, by Celebrating World Wellness Weekend

With World Wellness Weekend due to be celebrated on the 19th and 20th of September, Sharjah Ladies Club announced that they will be participating in the event for the second time with a range of both physical and virtual activities. Sharjah Ladies Club aims to bring women towards one goal by empowering and inspiring them to lead a healthier lifestyle, as well as providing opportunities to develop their skills and relax in world-class facilities while taking all safety precautions.


Continue Reading >

September 15, 2020


Re-opening of Algerian schools depends on COVID-19 situation:PM

Algerian Prime Minister Abdelaziz Djerad on Sunday said that the date for the start of the 2020-2021 school year depends on the COVID-19 situation in the country, the official APS news agency reported.

Djerad told media that the scientific committee monitoring the spread of COVID-19 will provide its professional suggestion for the date of opening schools to the government.


Continue Reading >

September 14, 2020


Phase II trial results demonstrated improvement in cognition with BI 425809 in adult patients with schizophrenia

  • Results presented at the 33rd ECNP Congress from a 12-week, placebo-controlled Phase II trial demonstrated BI 425809 has met its primary endpoint1,2
  • Trial results, together with an ongoing combination Phase II study of BI 425809 and adjunctive computerized cognitive training, add to the body of evidence for Boehringer Ingelheim’s schizophrenia research program3
  • Cognitive impairment associated with schizophrenia (CIAS) has a significant negative impact on daily functioning and remains a focus for Boehringer Ingelheim’s research across several neuropsychiatric...

    Continue Reading >

Forex News Headline

Forex Market Video